Lane & Associates LLC Increases Holdings in Johnson & Johnson (NYSE:JNJ)

VaselineSeptember 11, 2024

0 4 minutes read

Lane & Associates LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,251 shares of the company’s stock after buying an additional 111 shares during the period. Lane & Associates LLC’s holdings in Johnson & Johnson were worth $621,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Norges Bank bought a new stake in Johnson & Johnson in the 4th quarter valued at $4,071,642,000. Wellington Management Group LLP boosted its stake in shares of Johnson & Johnson by 16.4% during the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after acquiring an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after buying an additional 3,139,499 shares during the period. Dimensional Fund Advisors LP grew its holdings in Johnson & Johnson by 10.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock valued at $1,593,908,000 after buying an additional 975,485 shares during the period. Finally, Ninety One UK Ltd grew its position in Johnson & Johnson by 59.0% during the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company’s stock valued at $980,579,000 after purchasing an additional 2,489,925 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s shares.

Johnson & Johnson stocks rose 0.5%

NYSE:JNJ opened at $167.38 on Wednesday. The firm has a 50 day simple moving average of $158.40 and a two hundred day simple moving average of $153.85. The firm has a market cap of $402.92 billion, a P/E ratio of 10.44, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85, and a current ratio of 1.07.

Want more great investment ideas?

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.80 EPS. analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider work at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. 0.16% of shares are held by insiders.

Analysts set new price targets

A number of brokerages recently weighed in on JNJ. Morgan Stanley lifted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $160.00 to $150.00 in a report on Tuesday. July 23. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Moderate Buy” and an average target price of $173.21, according to MarketBeat.com.

Read our latest report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.